Obinutuzumab Delays Disease Progression in CLLMonthly Prescribing Reference… obinutuzumab (GA101) plus chlorambucil helped patients with previously untreated chronic lymphocytic leukema live significantly longer without their disease worsening (progr…
|
Atlas leads €2.5m round for Harbour Antibodies
unquote news (subscription) The company has engineered two types of transgenic mice, H2L2 and HCAb. The mice are designed to generate human antibodies. According to Harbour, the engineering of these transgenic mice means that all licensed pharmaceutical and biotechnology … |
|
Harbour Antibodies BV Raises ‚Ǩ2.5M ($3.3M) to Accelerate the Development …
PharmiWeb.com (press release) Harbour Antibodies BV the creator of transgenic mice to aid in the discovery of new human antibody-based therapies has raised ‚Ǩ2.5M ($3.3M) to continue R&D and commercialize its technologies. The round was led by Atlas Venture. With the funding … Atlas leads €2.5m round for Harbour Antibodiesunquote news (subscription) |
|
Pneumonie à Pneumocystis : une complication des traitements par rituximab
Journal International de Médecine (Inscription) La pneumonie à Pneumocystis (PP) reste une infection fongique grave affectant les malades immunodéprimés. Les défenses immunitaires principales contre ce germe opportuniste sont constitués classiquement par les lymphocytes T CD4 +. Mais des études … |
|
Harbour Antibodies BV Raises €2.5M ($3.3M) to Accelerate the Development of …
PipelineReview.com (press release) ROTTERDAM, The Netherlands & CAMBRIDGE, MA, USA I July 24, 2013 I Harbour Antibodies BV, the creator of transgenic mice to aid in the discovery of new human antibody-based therapies, has raised €2.5M ($3.3M) to continue R&D and commercialize … |
|
Harbour Antibodies BV Raises €2.5M ($3.3M) to Accelerate the Development of …
Fort Mills Times Harbour Antibodies BV, the creator of transgenic mice to aid in the discovery of new human antibody-based therapies, has raised €2.5M ($3.3M) to continue R&D and commercialize its technologies. The round was led by Atlas Venture. With the funding … Harbour Antibodies Licenses H2L2 Mice to PfizerPharmiWeb.com (press release) Atlas leads €2.5m round for Harbour Antibodiesunquote news (subscription) Pfizer licenses antibody tech from Atlas-backed startup HarbourFierceBiotech |
Astellas receives US approval for tacrolimusZenopaThe drug will be known as Astagraf XL in the US and is intended for use among patients with mycophenolate mofetil and corticosteroids, both with and without basiliximab induction. Approval was granted b…
Roche antibody tops Rituxan in blood cancer CLLPMLiVERoche said updated results from a phase III study of obinutuzumab (formerly GA101) showed the anti-CD20 antibody improved progression-free survival (PFS) in people with CLL compared to its establishe…
|
Genentech’s Obinutuzumab (GA101) Delayed Disease Progression Longer …
Wall Street Journal … monitoring committee determined that the study met its primary endpoint showing that GA101 plus chlorambucil helped people live significantly longer without their disease worsening (progression-free survival; PFS) compared to Rituxan(R) (rituximab … |
|
Genentech’s Obinutuzumab (GA101) Delayed Disease Progression Longer …
Fort Mills Times … monitoring committee determined that the study met its primary endpoint showing that GA101 plus chlorambucil helped people live significantly longer without their disease worsening (progression-free survival; PFS) compared to Rituxan® (rituximab … |